Alkermes Q2 Revenue Jumps 27% to $496M, Medicaid Rebate Shifts in Focus
ALKS sits 97% above its 52-week low of $25.165.
Summary
Alkermes reported Q2 2026 revenue of $496.0M, a 27% year-over-year increase, with GAAP EPS of $0.00 and net income of just $0.5M. The top-line growth is significant, but profitability remains razor-thin. Management highlighted that channel mix and gross-to-net changes, particularly the inclusion of LUMRYZ, have altered Medicaid rebate favorability and shifted deduction composition—though no quantified impact was provided. Shares have already surged 88.5% year-to-date, suggesting high expectations are priced in. The Medicaid rebate dynamics introduce uncertainty around future margins, which could weigh on sentiment if not clarified. This follows positive trial results for an experimental drug in June, adding to the narrative of pipeline momentum. Investors will look for more detail on the rebate impact in the upcoming earnings call.
At the time of this announcement, ALKS was trading at $49.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2B. The 52-week trading range was $25.17 to $55.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.